Early Detection and Interception of Lung Cancer
- PMID: 38724286
- DOI: 10.1016/j.hoc.2024.03.004
Early Detection and Interception of Lung Cancer
Abstract
Recent advances in lung cancer treatment have led to dramatic improvements in 5-year survival rates. And yet, lung cancer remains the leading cause of cancer-related mortality, in large part, because it is often diagnosed at an advanced stage, when cure is no longer possible. Lung cancer screening (LCS) is essential for intercepting the disease at an earlier stage. Unfortunately, LCS has been poorly adopted in the United States, with less than 5% of eligible patients being screened nationally. This article will describe the data supporting LCS, the obstacles to LCS implementation, and the promising opportunities that lie ahead.
Keywords: Artificial intelligence; Cancer risk; Disparities; Early detection; Lung cancer; Lung cancer screening.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Dr L.V. Sequist receives institutional research support from AstraZeneca, United Kindom, Novartis, Switzerland, Delfi Diagnostics, United States, and participates in a clinical demonstration project funded by Grail, United States.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical